If your Crohn's is in remission and you are still exhausted, the most useful thing to know first is that you are in the majority, not the exception. A systematic review with meta-analysis of 20 studies put the pooled prevalence of fatigue at 47% among people with IBD in remission, against 72% in active disease (D'Silva 2022). Remission moves the number, but it does not empty the room.
The second thing worth knowing is that this is almost never a sign that your treatment is failing in secret. When researchers took blood from people whose Crohn's or colitis was quiet on both symptoms and colonoscopy, the fatigued group did not have higher inflammatory cytokines than the non-fatigued group (Borren 2021a). Something is going on, but it is usually not a smouldering flare.
This guide is about the fatigue that stays after the gut settles down. It covers what the evidence says is actually driving it, what is worth having checked, what the treatment trials found including the large one that failed, and how to describe it to people who hear the word "tired" and think of their own Tuesday.
The short answer: this is a recognised part of Crohn's, not a personal failing
Fatigue in IBD is common enough that it appears in review articles as one of the defining extraintestinal problems of the disease, described as affecting close to half of patients in clinical remission and more than 80% of those with active disease (Borren 2019).
Those two numbers, "80% active, 50% in remission", are the ones you will see on almost every patient information page about IBD and fatigue. They are not wrong, but they come from narrative review statements rather than from a pooled analysis. When a meta-analysis did the pooling, it landed slightly lower, at 72% in active disease and 47% in remission, and it reported an I-squared of 98%, meaning almost all the variation between studies came from real differences in how they defined and measured fatigue rather than from chance (D'Silva 2022). The same paper showed how much the definition moves the number: using a "chronic fatigue" threshold gave 28%, while "high fatigue" gave 48%.
So the honest version is: somewhere between a quarter and a half of people with IBD in remission have fatigue serious enough to count, depending on where you draw the line. That is a wide band. It is still a lot of people, and it means a doctor who is surprised by your complaint is out of step with the literature.
What it also means is that "your scopes are clean, so you should feel fine" is not a clinical fact. It is a guess that the evidence does not support.
What Crohn's fatigue actually feels like, and why "tired" is the wrong word
The single most useful thing the patient community has produced on this topic is a set of analogies, and they are strikingly consistent. Across threads in r/CrohnsDisease asking what the fatigue feels like, the most upvoted answers almost never use the word tired. They describe a phone left on the charger for two hours that has gained two percent. Driving with the brakes on: pressing hard, moving slowly. Filling a fuel tank that has a hole in the bottom. Walking through quicksand (r/CrohnsDisease thread).
One commenter in a different thread described telling their therapist they had "50 percent battery today", and being met with sympathy, before realising that 50 percent was roughly as good as their days get (r/CrohnsDisease thread).
These are not just colourful descriptions. They capture something the research instruments try to measure: fatigue in chronic illness behaves like a mismatch between the energy a task demands and the energy available, rather than like sleepiness. That is why extra sleep so often does not help, and why the common advice to "get an early night" misses the point. In the largest UK survey of these symptoms, 8,486 people with IBD rated fatigue as the most severe of the three symptoms studied, ahead of faecal incontinence and pain, and 56% said they "definitely" wanted help with it (Hart 2024). Fatigue was the symptom people wanted addressed most and, in most clinics, the one that gets addressed least.
Is it hidden inflammation? The evidence says usually not
This is the question that sends most people to search in the first place, and the answer across several studies is reassuring in one sense and frustrating in another.
The cleanest study enrolled 166 people whose IBD was quiescent both clinically and on colonoscopy, 106 with Crohn's and 60 with ulcerative colitis. Fifty-five percent were fatigued. When the researchers compared serum from the fatigued and non-fatigued groups, they found no significant increase in inflammatory cytokines in the fatigued group. What they did find was a different metabolic signature: a cluster of 18 serum metabolites differed significantly, with lower methionine, tryptophan, proline and sarcosine in the fatigued group, alongside a less diverse gut microbiome (Borren 2021a).
A Norwegian multicentre study of 405 people with IBD pointed the same way from a different angle. Higher fatigue scores were associated with higher disease activity scores, which are symptom-based, but not with raised CRP or faecal calprotectin (Frigstad 2018). In other words, fatigue tracked how people felt, not what the objective markers showed.
A systematic review of 22 studies covering 16,927 people made this explicit: clinical assessment of disease activity was associated with more severe fatigue, but objective assessment was not (Conley 2025).
The contradiction worth printing. Not every study agrees. An Italian survey of IBD outpatients found that an abnormal CRP was independently associated with severe fatigue, with an odds ratio of 5.1, alongside severe anxiety (3.7) and sarcopenia (4.4) (Tasson 2021). That looks like the opposite finding. Two caveats are worth knowing before you weigh it: only 99 of 244 invited patients responded, a 40.5% response rate that invites selection bias, and the population was not restricted to people in remission, so some of the CRP signal may be coming from people with active disease.
The practical upshot is not "inflammation is irrelevant". It is that a clean calprotectin does not rule out real fatigue, and persistent fatigue is weak evidence for hidden inflammation. If you want to know whether you are inflamed, the test answers that, not the tiredness. Our post on what a high calprotectin with no symptoms actually means covers the same discordance running in the opposite direction.
There is also early imaging work suggesting the brain is involved. In a study of 92 people with Crohn's and 41 controls, associations between intrinsic brain activity and extraintestinal symptoms including fatigue were detected particularly in the remitted state (Thomann 2025). That is a small, exploratory functional MRI study and it does not translate into anything you can act on today, but it makes the point that fatigue after remission is a biological phenomenon with a plausible substrate, not a motivational one.
What is worth checking, and what each result would and would not explain
Before assuming there is nothing to be done, it is worth knowing what a reasonable workup looks like, so you can ask which parts of it you have actually had. This table is a conversation prompt for your IBD team, not a self-diagnosis tool.
| What gets checked | Why it comes up | What a normal result rules out |
|---|---|---|
| Full blood count and haemoglobin | Anaemia affects around 24% of people with IBD in European cohorts (Filmann 2014) | Anaemia, but not iron deficiency without anaemia |
| Ferritin plus transferrin saturation | Iron deficiency can exist with a normal haemoglobin, and ferritin behaves differently when inflammation is present | Less than people assume, which is why both are usually needed |
| B12, with methylmalonic acid if borderline | Terminal ileal disease and ileal resection are the classic reasons B12 drops in Crohn's | True deficiency, but only if MMA was included |
| Thyroid function | A routine, cheap alternative explanation for fatigue in any population | A thyroid cause |
| CRP and faecal calprotectin | To answer the inflammation question separately, since fatigue itself does not answer it | Active inflammation, which is useful information regardless |
| A conversation about sleep and mood | The two factors most consistently associated with IBD fatigue in the literature | Nothing, but it is where most of the modifiable ground sits |
Iron: the deficiency with the strongest case
Iron is where the evidence for a correctable cause is least shaky. Anaemia in IBD sits around 24% overall in European data, rising with active disease and slightly more common in Crohn's than ulcerative colitis (Filmann 2014). A 2025 review of iron deficiency in adults lists fatigue, difficulty concentrating, exercise intolerance and restless legs among its symptoms, and names inflammatory bowel disease as a risk factor with a reported prevalence range of 13% to 90% (Auerbach 2025). That range is enormous because different studies define iron deficiency differently, which is itself the recurring problem in this literature. Our guide to ulcerative colitis fatigue and low iron goes through ferritin cut-offs, tablets versus infusions and how quickly deficiency comes back.
Iron deficiency without anaemia is the version most often missed, and its link to fatigue is weaker than commonly claimed. A 2025 systematic review found seven eligible studies covering 1,425 people, and concluded that the methods varied so much that no quantitative synthesis was possible. Of the three studies that directly compared people with iron deficiency without anaemia to those who were iron replete, two found a statistically significant difference, and the review's own conclusion characterises this as evidence of "a slight increase in fatigue levels". The authors are explicit that this does not explain all fatigue in IBD (Sartain 2025).
On treatment, a Cochrane review of iron interventions in IBD concluded that intravenous ferric carboxymaltose probably resolves iron deficiency anaemia more often than intravenous iron sucrose, and that intravenous iron delivery probably produces a greater response than oral iron, with a number needed to treat of 11. The certainty of most findings was low or very low, and the authors specifically flagged that outcomes such as fatigue were poorly reported, leaving an evidence gap (Gordon 2021).
A note on sourcing: the European Crohn's and Colitis Organisation published a consensus on iron deficiency and anaemia in IBD which is the document most clinicians work from (Dignass 2015). It is not open access and I could not read its full text this run, so I am not quoting its ferritin thresholds here. If you want the specific numbers your team uses, ask them directly rather than trusting a number repeated on a blog.
A recurring theme in the Crohn's threads is people starting iron on their own after reading exactly this kind of article, and one of the most sensible replies in a 2025 thread pointed out that it makes more sense to get levels checked first, since oral iron is hard on some people's stomachs (r/CrohnsDisease thread). Whether to take anything is a decision for you and your clinician, and testing first makes that conversation a short one. If you menstruate, the monthly iron loss is a genuine and frequently overlooked contributor, which we cover in more detail in why Crohn's gets worse around your period.
B12: less common than the internet suggests
B12 gets mentioned constantly in Crohn's fatigue threads, usually with good reason, since the terminal ileum is where B12 is absorbed and it is also where Crohn's most often sits. But the prevalence is lower than the folklore implies once you test properly.
In a prospective study of 96 people with IBD, serum B12 below the reference range was found in 7.6% of those with Crohn's and 10% of those with ulcerative colitis. When true deficiency was defined properly, low B12 plus raised methylmalonic acid, the figures fell to 3% and 3.3%. People with ileal resections longer than 30 cm had significantly lower mean B12 levels and a trend toward more results below the reference range, although not more confirmed deficiency in this small sample (Battat 2017).
So: worth checking, particularly after ileal resection, but a normal B12 is the more likely result and it will not be the answer for most people.
Vitamin D: the honest null
Vitamin D is the supplement most often suggested in fatigue threads. The best-designed study to look at it directly in IBD did not support it. Among 405 people across nine Norwegian hospitals, half were vitamin D deficient by the study's threshold, 29% reported chronic fatigue and 48% substantial fatigue. After adjusting for age, sex, disease activity, depressive symptoms and sleep disturbance, vitamin D levels were associated with neither total fatigue scores nor chronic fatigue (Frigstad 2018).
That is a cross-sectional study, so it cannot rule out a benefit from correcting a genuine deficiency, and vitamin D is checked in IBD for reasons that have nothing to do with fatigue. But as an explanation for why you are exhausted in remission, it performed poorly when tested.
Sleep is the contributor with the most leverage
If there is one modifiable factor to take seriously, this is it, on two separate grounds.
First, sleep quality is the most consistent correlate of IBD fatigue in the literature. A systematic review of 22 studies covering 16,927 people found 56.1% experienced fatigue and 66.3% sleep deficiency, and that sleep quality and insomnia were consistently associated with fatigue. Poor sleep quality at baseline was associated with persistent and worsening fatigue over the following 12 to 24 months (Conley 2025).
Second, sleep disturbance is the single strongest predictor of developing fatigue you did not previously have. In a prospective study nested in the IBD Partners cohort, among people who were not fatigued at baseline, 26% became fatigued within six months, and the strongest predictor was baseline sleep disturbance, with an odds ratio of 2.91 (Borren 2021b).
The same study gives the sobering counterpart: persistent fatigue at both time points was the most common pattern, affecting 65.8% of participants, and only 12.3% of those fatigued at baseline had resolution at six months. Resolution was more likely in people with ulcerative colitis, quiescent disease, and no significant psychological comorbidity.
There is also a reason to care about sleep beyond the fatigue itself. In an analysis of 1,291 people with Crohn's in clinical remission, those with impaired sleep had double the risk of active disease six months later, an adjusted odds ratio of 2.00. Notably, this effect was seen in Crohn's and not in ulcerative colitis, where the odds ratio was 1.14 and not significant (Ananthakrishnan 2013). This is an observational finding and cannot establish that fixing sleep prevents flares, but it makes sleep a legitimate item for your Crohn's appointment rather than a lifestyle aside. Our post on stress, anxiety and Crohn's flares goes further into why sleep has the cleanest evidence of any gut-brain factor in this disease.
Mood, and why raising it does not mean the fatigue is "in your head"
Anxiety and depression show up as fatigue risk factors in nearly every study in this field, including the pooled meta-analysis, which named sleep disturbance, anxiety, depression and anaemia as the most commonly reported associated factors (D'Silva 2022). In the Italian survey, severe anxiety was independently associated with severe fatigue with an odds ratio of 3.7 (Tasson 2021).
The reason this is worth knowing is practical rather than philosophical. Psychological comorbidity was one of the factors that predicted whether fatigue resolved over six months (Borren 2021b). If low mood is part of the picture, it is one of the few parts with treatments that exist.
None of that means the fatigue is imaginary, and the association runs in both directions. Being exhausted for years, cancelling plans, and having people tell you that you look fine is a reliable route into low mood on its own.
Your medication might be part of it, and that is worth asking about
Immunomodulators are a real and under-discussed contributor. In a retrospective cohort of 782 people started on thiopurines or methotrexate for IBD, 27% discontinued therapy because of adverse events, and fatigue specifically was the documented reason in 7% of methotrexate recipients versus 2% of those on thiopurines. Overall discontinuation for adverse events was 40% on methotrexate against 19% on thiopurines (Vasudevan 2020).
That is a retrospective single-region study and it counts discontinuations rather than measuring fatigue with an instrument, so it understates how many people feel washed out and carry on anyway. But it establishes that this is a recognised, documented effect and not something you invented.
Do not change anything yourself. The useful move is to name the timing precisely at your next appointment: if the exhaustion is reliably worse for 36 hours after a weekly injection, that is a pattern your team can do something with, and it is exactly the kind of detail that disappears from memory by the time you are in the room. Our post on questions to ask your doctor about Crohn's disease covers how to get that on the agenda.
Caffeine gets raised constantly in the threads as a partial workaround, and several commenters note it helps a little and stops working. That is worth weighing against its effect on sleep, which we cover in whether you can drink coffee with Crohn's.
Muscle, deconditioning, and the loop that keeps it running
Sarcopenia, meaning loss of muscle mass and strength, was independently associated with severe fatigue in the Italian survey with an odds ratio of 4.4 (Tasson 2021). This matters because it is the piece of the puzzle that is self-reinforcing: being exhausted reduces activity, reduced activity costs muscle and cardiorespiratory fitness, and lower fitness makes every task cost more energy.
One commenter in a Crohn's thread described exactly this loop, having gained weight while being undernourished, too tired to be active, and feeling worse the more active they tried to be (r/CrohnsDisease thread). Years of restrictive eating during flares can leave someone both overweight and nutritionally depleted, a combination our post on what to eat during a Crohn's flare goes into in more detail.
A systematic review of the impact of IBD fatigue on quality of life found physical activity cut both ways: higher fatigue impaired activity and lowered quality of life, but activity was also used by patients as a means of reducing fatigue (Radford 2021). The review noted methodological shortcomings across the included studies, so this is a direction of travel rather than a proof. Our guide to exercising with Crohn's disease covers what the Crohn's-specific evidence shows and which situations change what is sensible.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
What the treatment trials actually found
This is where most articles get vague. Here is the honest state of it, including the failures, because the failures are the most informative part.
| Intervention | What was tested | Result |
|---|---|---|
| Biologics and small molecules | Meta-analysis, 7 induction RCTs, 3,835 people, active disease only | Small but consistent benefit over placebo, SMD 0.25 (95% CI 0.15 to 0.34) (Skjellerudsveen 2023) |
| Digital CBT self-management (IBD-BOOST) | RCT, 780 people randomised | No significant difference in quality of life or symptom relief at 6 months (Moss-Morris 2025) |
| Personalised exercise programme | Pilot, 25 people, quiescent IBD, no control group | Fatigue score fell from 105 to 66 on the CIS (van Erp 2021) |
| Psychological therapy, pooled | Systematic review, 4 RCTs | Promising effect sizes for CBT, all non-significant, all underpowered (Emerson 2021) |
| Multistrain probiotic | RCT, 100 people, quiescent IBD | No benefit over placebo at 12 weeks (Borren 2026) |
| B vitamins plus magnesium | RCT, 98 people in remission, 4 weeks | Fatigue scores improved; quality of life did not (Ramezani 2026) |
| Low-dose naltrexone | RCT in active Crohn's, stopped early for futility | Missed its primary endpoint; fatigue improved as a secondary outcome (van de Pol 2026) |
The biggest trial was negative
IBD-BOOST was a multicentre UK randomised trial of a digital, facilitator-supported cognitive behavioural self-management programme aimed at fatigue, pain and faecal urgency. It randomised 780 people, recruited from those who had rated the impact of these symptoms at 5 or more out of 10 in a national survey. At six months there was no statistically significant difference in the UK-IBDQ quality of life score, with an adjusted mean difference of -1.67 (95% CI -4.13 to 0.80, p=0.19), and no significant difference on the other primary outcome, global rating of symptom relief (Moss-Morris 2025).
That is a null result on both primary endpoints in the largest trial this field has, and it should temper anyone's confidence that a self-management programme is the answer.
The accompanying process evaluation is where it gets interesting. Interviewers spoke with 30 participants before and 28 after the intervention. Those in the treatment arm reported high satisfaction, many were still using the strategies, and several described better symptom management and quality of life. The platform's own analytics, meanwhile, showed low adherence. The authors titled the paper to say plainly that their findings contradict the trial's results (Czuber-Dochan 2025).
Both things can be true: a programme that helps the people who complete it can still fail to move a population-level outcome when most participants do not complete it. That is a reason to be realistic about what a self-guided programme will do for you, not a reason to reinterpret a null as a positive.
The smaller studies look better, and that is partly why they look better
A meta-analysis of 11 non-pharmacological studies, covering problem-solving therapy, solution-focused therapy, CBT, psychoeducation, exercise advice with omega-3, electro-acupuncture and a mushroom extract, found a pooled standardised mean difference of 0.33 (95% CI 0.10 to 0.55, p=0.005) (Davis 2020). That is a small effect from a very mixed bag of interventions.
The individual studies are tiny. The solution-focused therapy study that gets cited most often randomised 29 people with quiescent Crohn's across three arms, and reported that fatigue scores improved in 85.7% of the solution-focused group, 60% of the problem-solving group and 45.5% of those receiving usual care (Vogelaar 2011). With 8 people in the best-performing arm, those percentages represent six or seven individuals.
The CBT trial most often described as positive was explicitly a feasibility study. Of 70 eligible people, 31 consented, 13 of 15 in the intervention arm started it, and 10 completed all eight sessions. Follow-up questionnaires were returned by 71% at three months but only 39% at twelve (Artom 2019). It was designed to answer whether a trial could be run, not whether the therapy works.
A systematic review of the psychological trials concluded that CBT produced the largest effect, a Hedges' g of 0.91 for fatigue severity at 12 months, but that the confidence interval ran from -0.30 to 2.11 and the result was non-significant because the studies were underpowered (Emerson 2021). A large effect size with a confidence interval straddling zero is a signal that more research is needed, not a treatment recommendation.
The recent nulls
Two 2026 trials are worth knowing about because they close off popular hypotheses.
A multicentre randomised trial gave 100 people with clinically and endoscopically quiescent IBD either a nine-strain probiotic or placebo for 12 weeks. At the end, 29.4% of the probiotic group and 40.0% of the placebo group no longer met the fatigue threshold, a non-significant difference favouring placebo numerically. Everyone improved, with the most striking change at four weeks in both arms, which is a textbook picture of regression to the mean plus placebo response. The probiotic did shift the microbiome and metabolome, just without relieving fatigue (Borren 2026). I did not read a conflict of interest statement for this trial.
The low-dose naltrexone trial is a cautionary tale in how a fatigue finding can be over-read. It randomised 41 people with active Crohn's, was stopped early for futility, and missed its primary endpoint of endoscopic remission at 12 weeks. Clinical remission actually favoured placebo, 70.0% versus 22.2%. The FACIT-Fatigue score did favour low-dose naltrexone, with a median change of 2.5 versus -3, p=0.012 (van de Pol 2026). That is a secondary outcome in a small trial that was stopped for futility and whose main comparisons went the wrong way. It is a hypothesis, not a finding.
The B vitamin and magnesium trial is the most genuinely promising of the recent set, randomising 98 adults with IBD in remission to four weeks of B1, B6, B12 and magnesium or placebo. Fatigue improved significantly on both sections of the IBD-Fatigue scale. But the quality of life measure did not move, and while the ulcerative colitis activity score improved, the Crohn's activity score did not (Ramezani 2026). Four weeks is short, one trial is one trial, and the authors themselves say effects on underlying inflammation remain uncertain. Do not start supplements on the strength of this; take it to your team.
Does getting into remission fix it? Partly
This is the question behind most of the threads, and there is a direct answer.
A prospective cohort followed 326 people with IBD starting a biologic, tracking fatigue at weeks 14, 30 and 54. Sixty-one percent were fatigued at the start. Among the 198 who were fatigued at initiation, 70% were still fatigued at week 14, 63% at week 30 and 61% at week 54. Achieving clinical remission was associated with a lower likelihood of persistent fatigue at every time point. And yet, among those who did achieve remission, 35%, 30% and 28% were still fatigued at those same visits (Borren 2020).
So remission moves the odds substantially and is worth pursuing for this reason among many others, but roughly three in ten people who get there stay fatigued a year on. If that is you, you are describing something the data anticipated.
The induction-trial meta-analysis says the same thing in a different register: a small, consistent benefit of biologics and small molecules on fatigue, SMD 0.25, independent of drug type or IBD subtype, and the authors note the trials were not designed to evaluate fatigue at all (Skjellerudsveen 2023). Those trials also enrolled people with moderately to severely active disease, so the result does not transfer to someone already in remission.
"Does needing a nap mean a flare is coming?"
Not on its own, and the evidence points somewhere slightly different.
The prospective signal is disturbed sleep, not daytime napping. Impaired sleep in Crohn's remission was associated with roughly double the risk of active disease six months later (Ananthakrishnan 2013), and disturbed sleep was the strongest predictor of newly developing fatigue (Borren 2021b). A two-hour nap after work in someone whose bowel pattern is stable is, on the evidence, most likely just fatigue.
What does warrant attention is change. A shift from your usual level of exhaustion, especially one arriving alongside altered stool frequency, abdominal pain, blood, weight loss, fever or night sweats, is a different thing from your steady baseline. That combination is what our post on how to tell if you are in a Crohn's flare is built around, and it is the reason a baseline is worth having before you need one.
It is worth knowing that fatigue is not directly scored in the activity index many Crohn's clinics use. The Harvey-Bradshaw Index has a general wellbeing item that can absorb some of it, but nothing that measures fatigue specifically, which is one reason it can vanish from the clinical record entirely. We unpack what that score does and does not capture in how to interpret a Harvey-Bradshaw Index.
A worked example: eight weeks to a useful appointment
Here is what turning this into something actionable looks like in practice. The point is not to log everything. It is to arrive with three or four specific claims that can be checked.
Weeks 1 to 2. Rate fatigue once daily on a 0 to 10 scale, at roughly the same time, alongside hours slept, number of night wakings, and any medication taken that day. Nothing else. Two weeks is enough to see whether your bad days cluster.
Weeks 3 to 4. Add one line about what the fatigue cost you. Not "tired", but "cancelled dinner", "could not cook", "slept in the car before driving home". These are the units clinicians can use, and they are what you will forget.
Weeks 5 to 6. Look for the two patterns that most often show up. First, does fatigue follow your injection or infusion schedule with a consistent lag? Second, do your worst fatigue days follow your worst sleep nights, or do they arrive independently?
Weeks 7 to 8. Write one page. Top line: average fatigue rating, worst week, number of days it changed what you did. Then the two or three patterns you found, with dates. Then your questions: what has been tested and when, whether ferritin and transferrin saturation were both done, whether sleep has ever been assessed, and whether the timing relative to medication is plausible.
That last page is the part that changes the conversation, because "I am always tired" and "my fatigue averaged 7 out of 10, cost me eleven planned activities in eight weeks, and the worst days are the two after my methotrexate" are received completely differently. Our guide to building a symptom summary your doctor will actually read covers the formats that survive a ten-minute appointment. If you would rather not keep this on paper, Clairop logs symptoms alongside the things that might be driving them and produces a one-page summary for appointments. No app can tell you whether you are inflamed; only a test does that.
How to describe it so people believe you
The "I'm tired too" problem comes up so often in the Crohn's community that there are dedicated threads about it, and the frustration in them is consistent: the word tired maps onto something universal, so using it invites comparison rather than understanding.
Three things seem to work better than adjectives.
Use the cost, not the feeling. "I have to choose between cooking dinner and going out afterwards" is unarguable. "I am really tired" is an invitation to be told everyone is.
Use an analogy and commit to it. The battery framing is the most widely used in these threads for a reason: it makes the idea of a hard limit intuitive, and it makes "rest" sound like something other than laziness. One person described answering "how are you" with a battery percentage, which turned an unanswerable question into a number their therapist could work with.
Name the one thing that would help. People generally want to help and do not know how. "I would rather see you at mine than go out" or "can we move this to lunchtime" is easier to act on than a description of exhaustion.
A commenter in one thread mentioned something a home-visit nurse had said that stuck with them: that being tired makes sense because the body is behaving as though it is fighting something constantly. As an explanation of mechanism that is loose at best, and it is not how the cytokine data in quiescent disease actually look. But as a way of giving yourself permission to stop apologising, it clearly did its job, which is a different kind of usefulness.
Myths worth retiring
"If your scopes are clear, the fatigue should have gone." Roughly half of people with IBD in remission report fatigue in the pooled data, and 28% of people who reached clinical remission on a biologic were still fatigued a year later. The expectation is the thing that is wrong, not you.
"It must be inflammation you cannot see." In endoscopically quiescent disease, fatigued and non-fatigued patients had similar inflammatory cytokine levels, and in a 405-person study fatigue was not associated with CRP or calprotectin. One study found an association with abnormal CRP, so this is not settled, but hidden inflammation is not the default explanation.
"Take vitamin D, everyone with Crohn's is low." Vitamin D levels were associated with neither total fatigue nor chronic fatigue in the largest study to test it directly, after adjustment. Deficiency is worth correcting for other reasons; it is a poor bet as the explanation for your fatigue.
"It is just a B12 problem." True B12 deficiency, confirmed with methylmalonic acid, was found in about 3% of people with IBD in a prospective study. It is worth checking, especially after an ileal resection, and it will not be the answer for most people.
"Nothing works, so there is no point asking." The largest trial was negative, which is genuinely disappointing. But anaemia, poor sleep and low mood all have treatments, all three are associated with fatigue across studies, and all three are things a clinic can act on. The absence of a fatigue drug is not the absence of anything to do.
"You should push through it." The trial evidence for graded activity is thin and uncontrolled, but the sarcopenia and deconditioning findings suggest that complete inactivity has a cost of its own. Neither pushing through nor stopping entirely is supported; building gradually with guidance is the middle path the evidence weakly favours.
When to see a doctor promptly
Fatigue that has been stable for years is different from fatigue that has changed. Contact your IBD team promptly if you notice:
- Blood in your stool, or black or tarry stools
- Unintentional weight loss
- Fever, or drenching night sweats
- New or worsening abdominal pain, especially pain that comes in waves with vomiting, bloating and no passage of wind or stool, which can indicate a bowel obstruction and needs urgent assessment rather than a routine appointment, particularly if you have known narrowing or have had surgery
- Marked breathlessness, dizziness, chest pain or a racing heart, which can accompany significant anaemia
- Fatigue that worsens sharply over days to weeks rather than staying at its usual level
- Symptoms waking you at night
- A new lump, abscess or perianal pain alongside the fatigue
Fatigue on its own, unchanged, is a reason for a planned conversation rather than an urgent one. Fatigue that has clearly shifted, or that arrives with any of the above, is a reason to call.
The honest bottom line
Fatigue that persists after Crohn's goes quiet is one of the most common and least treated problems in the disease. It is reported by roughly half of people in remission, it is usually not a sign of hidden inflammation, and the single largest trial of a treatment for it produced a null result on both primary outcomes.
That sounds bleak written down, but the practical picture is better than it reads. The contributors with the most evidence behind them, sleep quality, mood, iron status, muscle loss and medication timing, are all things a clinic can assess and in most cases act on. Nobody can promise that addressing them ends the fatigue, and it would be dishonest to imply otherwise. What the evidence supports is that these are the levers, that remission improves the odds without guaranteeing anything, and that arriving at your appointment with eight weeks of specific, dated observations is the difference between being told to get more sleep and being investigated.
You are not imagining it, you are not failing at remission, and the literature has been describing your experience for over a decade.
